| Previous Close | 73.42 |
| Open | 73.32 |
| Bid | 73.76 x 100 |
| Ask | 74.08 x 100 |
| Day's Range | 73.28 - 74.41 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 8,874,021 |
| Avg. Volume | 8,651,084 |
| Market Cap | 96.38B |
| Beta | 0.96 |
| PE Ratio (TTM) | 7.80 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.83%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Motley Fool•12 hours ago
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
With big biotechs Celgene and Gilead Sciences, it's a battle of growth stock versus income/value stock.
- Investor's Business Daily•yesterday
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas'
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
- Barrons.com•yesterday
Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter?
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
